Systemic adjuvant therapies in renal cell carcinoma

od Sebastiano Buti, Melissa Bersanelli, Maddalena Donini, Andrea Ardizzoni
Izdano 2012-10-01

Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review

od Melissa Bersanelli, Matteo Brunelli, Letizia Gnetti, Umberto Maestroni, Sebastiano Buti
Izdano 2020-05-01

CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors

od Filippo G. Dall’Olio, Francesca Abbati, Francesco Facchinetti, Maria Massucci, Barbara Melotti, Anna Squadrilli, Sebastiano Buti, Francesca Formica, Marcello Tiseo, Andrea Ardizzoni
Izdano 2020-10-01

Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?

od Satoru Taguchi, Sebastiano Buti, Hiroshi Fukuhara, Masafumi Otsuka, Melissa Bersanelli, Teppei Morikawa, Hideyo Miyazaki, Tohru Nakagawa, Tetsuya Fujimura, Haruki Kume, Yasuhiko Igawa, Yukio Homma
Izdano 2017-01-01

Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors

od Matteo Santoni, Daniel Y. Heng, Sergio Bracarda, Giuseppe Procopio, Michele Milella, Camillo Porta, Marc R. Matrana, Giacomo Cartenì, Simon J. Crabb, Ugo De Giorgi, Umberto Basso, Cristina Masini, Fabio Calabrò, Maria Giuseppa Vitale, Daniele Santini, Francesco Massari, Luca Galli, Giuseppe Fornarini, Riccardo Ricotta, Sebastiano Buti, Paolo Zucali, Orazio Caffo, Franco Morelli, Francesco Carrozza, Angelo Martignetti, Alain Gelibter, Roberto Iacovelli, Alessandra Mosca, Francesco Atzori, Nuno Vau, Lorena Incorvaia, Cinzia Ortega, Marina Scarpelli, Antonio Lopez-Beltran, Liang Cheng, Vittorio Paolucci, Jeffrey Graham, Erin Pierce, Sarah Scagliarini, Pierangela Sepe, Elena Verzoni, Sara Merler, Mimma Rizzo, Giulia Sorgentoni, Alessandro Conti, Francesco Piva, Alessia Cimadamore, Rodolfo Montironi, Nicola Battelli
Izdano 2019-12-01